Loading...
Market
What will be the outcome of Neuralink's first Canadian trial by end of 2025?
2
Resolution / Starting Odds
Significant improvement in mobility • 25%
Moderate improvement in mobility • 25%
No improvement in mobility • 25%
Trial inconclusive • 25%
Successful with significant findings • 25%
Successful with limited findings • 25%
Unsuccessful • 25%
Indeterminate • 25%
Official trial results published by Neuralink or in scientific journals
Story
Neuralink Receives Approval for First Canadian Clinical Trial at Toronto Western Hospital
Nov 21, 2024, 10:30 AM
Neuralink, the neurotechnology company founded by Elon Musk, has received approval from Health Canada to begin recruitment for its first clinical trial in the country. The trial, part of the CAN-PRIME study, will be conducted at Toronto Western Hospital, marking the first non-U.S. site for Neuralink's brain implant tests. The study aims to assess the safety and initial functionality of the N1 chip, a wireless brain implant designed to allow paralyzed individuals to control digital devices using their thoughts. Recruitment is now open for quadriplegia patients, expanding on Neuralink's existing U.S. trials.
View original story
Similar markets
Recruitment completion • 25%
Initial results published • 25%
Trial expansion approved • 25%
Trial discontinued • 25%
Full success • 25%
Partial success • 25%
No success • 25%
Trial discontinued • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Successful with no issues • 25%
Successful with minor issues • 25%
Unsuccessful • 25%
Trial halted • 25%
Positive outcome • 25%
Negative outcome • 25%
Inconclusive outcome • 25%
Trial not completed • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%